Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB

Key Points

• Vident Advisory LLC has acquired 12,377 shares of Genmab A/S, valued at approximately $242,000, highlighting growing interest from institutional investors in the company.
• Recent analyst reports show a mixed outlook for Genmab A/S, with price target increases from Truist Financial and HC Wainwright, while Zacks downgraded the stock from "strong-buy" to "hold."
• Genmab A/S reported $0.54 EPS for the last quarter, exceeding expectations, and has a current market capitalization of $17.86 billion.

Vident Advisory LLC acquired a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 12,377 shares of the company's stock, valued at approximately $242,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marotta Asset Management grew its holdings in Genmab A/S by 5.8% in the 1st quarter. Marotta Asset Management now owns 13,532 shares of the company's stock valued at $265,000 after buying an additional 739 shares in the last quarter. Gallacher Capital Management LLC lifted its position in shares of Genmab A/S by 6.8% during the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock valued at $281,000 after acquiring an additional 915 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Genmab A/S by 27.2% during the 1st quarter. Smartleaf Asset Management LLC now owns 5,772 shares of the company's stock valued at $115,000 after acquiring an additional 1,236 shares during the period. Finally, Headlands Technologies LLC lifted its position in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GMAB shares. Truist Financial upped their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. Zacks Research downgraded Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, HC Wainwright upped their target price on Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus price target of $39.25.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.17 during trading hours on Monday, hitting $27.99. The company's stock had a trading volume of 1,540,531 shares, compared to its average volume of 1,383,707. The stock has a fifty day simple moving average of $23.70 and a 200-day simple moving average of $21.67. The company has a market capitalization of $17.96 billion, a P/E ratio of 14.07, a PEG ratio of 1.62 and a beta of 0.93. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $28.75.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.